Weight Loss
Articles tagged with Weight Loss
Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds
Review shows that obesity drugs and obesity surgery lead to a higher proportion of fat-free mass loss than diet and exercise interventions
Study suggests muscle mass preserved after obesity drug treatment
Trends in metabolic bariatric surgery utilization in the era of GLP-1s, 2022-2024
People who have lost weight using tirzepatide are seven times more likely to maintain their weight loss if they continue on the maximum dose compared to those who stop treatment
Study shows that most weight loss achieved using injectable obesity drugs can be maintained by switching to daily oral orforglipron (ATTAIN-MAINTAIN)
Study shows use of obesity drugs alongside behavioral intervention is associated with reduced “food noise”
Cannabis compounds may boost metabolic health while supporting weight loss
Researchers have identified potential mechanisms linked to reduced type 2 diabetes risk in chronic cannabis users. A team led by Nicholas V. DiPatrizio found that specific compounds within cannabis regulate metabolism, leading to significant weight loss and improved glucose regulation in obese mice.
Popular weight loss, diabetes drugs linked to improved breast cancer survival
A retrospective cohort study examining over 840,000 breast cancer patients found a potential link between GLP-1 RA use and improved outcomes among obese or diabetic patients. GLP-1 RAs were associated with lower risk of death and recurrence over a 10-year follow-up period.
New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
Pooled analysis of trails reveals semaglutide shows good efficacy in older adults aged over 65 years
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
Study shows for benefits on obesity-linked conditions of losing more weight with GLP-1 treatment
Bariatric surgery significantly more effective than GLP-1 drugs for weight loss and disease remission, large real-world study finds
A large real-world study comparing bariatric surgery to GLP-1 drugs found that surgery produced significantly greater weight loss and higher rates of obesity-related disease remission. After 12 months, patients who underwent surgery achieved more than 20% greater weight loss than those treated with GLP-1 therapy.
The critical role of exercise in the GLP-1 era
Regular physical activity is essential for mitigating the regain of lost weight after discontinuing GLP-1 medications. Exercise has complementary effects beyond energy balance, including improved insulin sensitivity and increased fat oxidation. Clinicians must develop individualized strategies to improve exercise adherence.
The GLP-1 paradox: Rice study finds weight loss drugs may carry unexpected stigma
A new study from Rice University finds that using GLP-1 medications can lead to social judgment, even among those who have lost significant weight. Participants rated individuals who used GLP-1 more negatively than those who lost weight through diet and exercise or did not lose weight at all.
New weight-loss mechanism without GLP-1 has fewer adverse GI side effects
Researchers have discovered a new weight-loss mechanism that eliminates the need for GLP-1, reducing gastrointestinal side effects and increasing treatment tolerability. This breakthrough offers hope for patients who struggle with adverse reactions to existing obesity medications.
New clinical trial shows vegan diet dramatically cuts food-related emissions—with major health benefits
A new randomized clinical trial shows that a low-fat vegan diet reduces greenhouse gas emissions by nearly three times more than a Mediterranean diet. The study also found significant improvements in key cardiometabolic outcomes, with the majority of environmental gains driven by eliminating meat, dairy, and eggs.
Weight-loss drugs could tackle Alzheimer’s – study
A new study found comprehensive evidence that weight-loss GLP-1 receptor agonists like semaglutide reduce amyloid-beta and tau buildup in the brain. Consistent reductions were seen in animal and cell studies, with liraglutide showing the most positive effects.
Simple ‘gut reset’ procedure may prevent weight rebound following GLP-1 discontinuation
A new procedure, duodenal mucosal resurfacing, has shown promising results in preventing weight regain after GLP-1 therapy discontinuation. The study found that patients who underwent the procedure maintained over 80% of their weight loss and regained less weight compared to those who received a sham procedure.
Postmenopausal white women with genetic risk regain weight two times faster
A new study has found that postmenopausal white women with higher genetic risk of obesity regained weight about two times faster than those with lower genetic risk. Despite this difference, Black women in the study regained weight at a similar rate, regardless of their genetic risk.
Weight-loss drugs may affect arthritis directly in the joints - new study finds
A new study from Aarhus University reveals that weight-loss drugs containing GLP-1 hormone may influence joint inflammation in arthritis patients. The study found that high doses of GLP-1 in medication could have a dual effect, both through weight loss and by increasing levels in the joints.
Medicare spending implications for semaglutide under voluntary price agreements
A lower semaglutide price could generate savings that offset the cost of treating an additional 550,000 to 3.6 million Medicare beneficiaries eligible for expanded obesity-indication coverage. This voluntary price agreement may lead to substantial savings for Medicare spending on semaglutide treatment.
Researchers identify mechanism for body weight-reducing hormone
A hormone called FGF21 reverses obesity in mice by signaling to the hindbrain, a region targeted by GLP-1 drugs. This finding provides insight into the naturally occurring hormone's benefits for weight loss and MASH treatment.
Want to lose weight? Try eating the same meals on repeat
Researchers found that adults who followed routine eating patterns lost more weight than those with varied diets. Those who repeated many of the same foods lost an average of 5.9% of their body weight, compared to 4.3%. Greater calorie consistency was also linked to better results.
Pythons’ feast-and-famine life hints at new weight-loss pathway
Researchers discovered a metabolite called pTOS in pythons that increases appetite suppression in obese mice, leading to significant weight loss. The study sheds light on the power of studying extremes in the animal kingdom and may lead to new weight-loss treatments.
Python blood could hold the secret to healthier weight loss
Researchers discovered an appetite-suppressing compound in python blood that promotes satiety without stomach problems. The compound, para-tyramine-O-sulfate, has potential for new weight loss treatments.
FAU researchers find concerning rise in US teen obesity over a decade
A concerning rise in adolescent obesity has been found, with overall rates climbing to 15.9% in 2023. Obesity patterns also reveal a decline in weight-loss attempts, with females more likely to attempt weight loss but fewer adolescents reporting efforts in 2023.
New genetic risk score better predicts diabetes, obesity and downstream complications
Researchers developed a comprehensive genetic risk calculator for metabolic disease by integrating genetic data from hundreds of thousands of people worldwide. The polygenic risk score outperformed existing disease-prediction models and predicted downstream morbidity and clinical interventions, particularly in non-European populations.
$3.4 million grant to improve weight-management programs
A $3.4 million NIH grant will fund a semi-automated feedback system to support people tracking diet, exercise, and weight in weight-management programs. The system aims to provide personalized feedback to increase tracking and weight loss success.
Wegovy may have highest ‘eye stroke’ and sight loss risk of semaglutide GLP-1 agonists
Analysis of unintended side effect reports reveals that Wegovy carries the highest risk of 'eye stroke' and sudden sight loss among semaglutide drugs, with odds nearly 5 times higher than Ozempic. The risk is particularly pronounced in men, with a signal nearly 3 times higher than in women.
GLP-1 diabetes drugs linked to reduced risk of addiction and substance-related death
A large US study published in The BMJ found that GLP-1 receptor agonists used to treat type 2 diabetes and obesity may also help lower the risk of addiction to various substances. The study associated GLP-1 receptor agonists with reduced risks of adverse outcomes such as overdoses and drug-related emergency department visits and deaths...
Patients regain weight rapidly after stopping weight loss drugs – but still keep off a quarter of weight lost
Patients who stop taking weight loss drugs like Ozempic and Wegovy experience rapid weight regain of up to 60% within a year, but sustain around 25% of lost weight. Researchers found that individuals may maintain healthier eating habits even after treatment ends.
Trends in metabolic and bariatric surgery use during the GLP-1 receptor agonist era
Semaglutide and tirzepatide prescriptions increased dramatically between 2018 and 2025, while MBS use rates declined substantially starting in 2023. Recent shifts in MBS use may be more pronounced in certain patient subgroups, such as those seeking sleeve gastrectomy or with lower BMIs.
GLP-1 drugs like Ozempic could cut risk of major heart complications after heart attack, study finds
GLP-1 weight-loss drugs may prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications. Researchers found that these drugs improve blood flow to the heart by activating potassium channels, relaxing constricted blood vessels and reducing heart damage risk.
Heterogeneity of treatment effects of GLP-1 RAs for weight loss in adults
A systematic review and meta-analysis found GLP-1 RAs produce significant weight loss across various subpopulations, including women who show improved outcomes compared to men. These findings have implications for clinical decision-making.
Science reveals why you can’t resist a snack – even when you’re full
A new study from the University of East Anglia found that the human brain continues to respond to tempting food cues even after eating enough. The research used EEG brain scans to monitor volunteers' brain activity as they played a reward-based learning game with food.
Understanding GLP-1 signaling: A path to better therapies
A new study finds that a novel GLP-1 receptor agonist, Exendin-4-Phe (Ex-Phe-1), preserves glycemic control while reducing malaise and vomiting behaviors in preclinical models. The compound uses biased agonism to selectively activate certain signaling pathways, achieving desired effects without triggering others.
The Lancet: New weight loss pill leads to greater blood sugar control and weight loss for people with diabetes than current oral GLP-1, phase 3 trial finds
A phase 3 trial found that orforglipron, a novel GLP-1 receptor agonist pill, leads to greater blood sugar control and weight loss than current oral GLP-1 RA semaglutide in people with type 2 diabetes. Participants taking orforglipron had significantly greater reductions in body weight and blood sugar levels.
It’s not just about the number on the scale: The hidden value of so-called “yo-yo dieting”
A new study by Ben-Gurion University of the Negev researchers found that repeated attempts at weight loss confer significant and sustainable health benefits over time, particularly through reduced visceral fat. Even when participants regain all the weight lost in a previous diet, their cardiometabolic health may remain improved.
Weight-loss wonder pills prompt scrutiny of key ingredient
A new study finds salcaprozate sodium may have adverse biological effects on the gut and beyond, including shifts in potentially harmful gut bacteria and elevated inflammatory markers. The research highlights an important gap in understanding the long-term impact of repeated SNAC exposure.
Evidence behind intermittent fasting for weight loss fails to match hype
A new Cochrane review suggests that intermittent fasting may not be an effective strategy for weight loss in overweight or obese adults. The study found no meaningful difference in weight loss between intermittent fasting and traditional dietary advice or doing nothing, highlighting the need for more research into this area.
Weight loss drug linked to lower risk of eye disease in patients with diabetes
A large-scale study found that patients taking tirzepatide had a significantly lower risk of developing new diabetic retinopathy or progressing to more severe stages. This suggests that the medication may not worsen eye health, offering relief for patients concerned about their vision.
Why people won’t quit a weight loss drug – even when it makes them feel sick
A Rutgers Health study found that perceived effectiveness of semaglutide, such as noticeable weight loss or reduced food cravings, was the strongest predictor of satisfaction and intention to continue treatment. Although gastrointestinal issues like nausea and vomiting were common, they didn't significantly influence satisfaction score...
Growth trajectories in infants from families with plant-based or omnivorous dietary patterns
A cohort study reveals that infants from vegan households have similar growth patterns to those from omnivorous households, with a higher risk of early underweight at birth. As the findings suggest, further research is needed to examine the quality of vegan diets and the impact of nutritional counseling during pregnancy and infancy.
Researchers quantify role of reducing obesity in preventing common conditions
Researchers have quantified the role of obesity in common long-term conditions, showing that losing weight can prevent multiple diseases. Obesity was found to be the main shared cause between ten pairs of commonly occurring conditions, such as type 2 diabetes and osteoarthritis.
Combined aerobic-resistance exercise: Dual efficacy and efficiency for hepatic steatosis
Researchers have found a nonlinear dose-response relationship between exercise and hepatic steatosis, indicating that a combination of aerobic and resistance exercises can produce clinically meaningful improvements. The study suggests that exercising above 130 MET-min/week can lead to significant reductions in hepatic steatosis.
UH study highlights need for conservative approach to unexplained unintentional weight loss evaluation
A recent study from University Hospitals Cleveland Medical Center found that diagnostic abnormalities were no more likely to occur among adults with unintentional weight loss than among comparison patients. In most cases, the weight loss was not linked to a serious underlying condition, with only a .7% overall rate of cancer.
Patient recruitment begins for major real-world digital weight management study
The W8Buddy study, a major real-world evaluation of digitally delivered specialist weight management pathways, is recruiting 450 participants from 4 Specialist Weight Management Services across England and Wales. The study aims to assess the long-term health benefits and economic impact of digital tools for obesity care.
Researchers develop way to make healthier sugar substitute
Tufts researchers have developed a method to biosynthetically produce tagatose, a rare sugar with potential health benefits. Tagatose is 92% as sweet as sucrose and has about 60% fewer calories, making it an attractive alternative to conventional sugar substitutes.
New study: How weight loss benefits the health of your fat tissue
A new study from University of Southern Denmark reveals that weight loss improves the health of fat tissue, reducing inflammation and immune cell activity. Moderate weight loss also promotes the formation of new and healthier fat cells, leading to improved insulin sensitivity.
Weight loss drugs and bariatric surgery improve the body’s fat ‘balance:’ study
Researchers at Vanderbilt Health found that both weight loss drugs and bariatric surgery induce a moderate loss of lean muscle and substantial reduction in fat, improving body composition in obese patients. This shift is associated with lower mortality risk from obesity-related diseases.
Study finds more than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss
A new study found that more than one-in-four adults worldwide may be eligible for GLP-1 use, with women and older individuals among the most eligible. The research emphasizes the need to prioritize global access to these medications, particularly in low- and middle-income countries where obesity rates are highest.
Lack of support for people on weight loss drugs leaves them vulnerable to nutritional deficiencies, say experts
Experts warn that people taking weight loss drugs like semaglutide and tirzepatide may not receive sufficient nutritional guidance, leaving them at risk of nutrient deficiencies and muscle loss. The lack of robust evidence surrounding nutritional advice and support has significant implications for overall health and well-being.
Health: estimated one in ten British adults used or interested in GLP-1 medications for weight loss
Around 4.9 million British adults, nearly one in ten, have recently used or expressed interest in GLP-1 medications to support weight loss. The demand highlights substantial need for these medications, which help lower blood sugar, support weight loss, and reduce the risk of heart and kidney complications.
1.6 million UK adults used weight loss drugs in past year
A new study found that 4.9 million adults in Great Britain have recently used a drug to support weight loss or were interested in using one in the near future. The usage far exceeds NHS England's initial goal of prescribing these drugs to 220,000 people over three years.
Stopping weight loss drugs linked to weight regain and reversal of heart health markers
A systematic review finds that stopping weight loss drugs leads to rapid weight regain, reversing heart health markers in under two years. Average monthly weight gain is 0.4kg, with all cardiometabolic risk markers projected to return to pre-treatment levels within 1.4 years.
Glucagonlike peptide-1 receptor agonists and asthma risk in adolescents with obesity
A recent study found that adolescents with overweight or obesity who take glucagonlike peptide-1 receptor agonists (GLP-1RA) have a lower risk of acute asthma exacerbations. This association suggests a potential dual benefit, where GLP-1RA use could address both weight management and asthma prevention in this population.
GLP-1s are changing the foods Americans buy
Households taking GLP-1 medications reduce grocery spending by an average of 5.3%, while spending at fast-food restaurants and coffee shops also decrease. Ultra-processed foods see significant declines, whereas yogurt, fresh fruit, and meat snacks experience modest increases.
Healthy Nordic diet good for both type 2 diabetes and non-alcoholic fatty liver disease
Researchers found that the healthy Nordic diet was more effective in reducing blood glucose levels and improving body weight, inflammation, and lipid profile compared to other diets. The study also showed that participants lost weight despite being allowed to eat as much as they wanted from recommended foods.